For the full information on the PhD projects available, please see below.

Thrombosis, encompassing arterial and venous thrombosis, and thromboinflammation, impacts the pathophysiology of major health issues such as heart attack, stroke, cancer and infection. Thrombosis contributes to an estimated 40% of cardiovascular deaths in the EU, and over €200 billion a year to the EU economy.

Current therapy in the prevention of arterial thrombotic events includes drugs that suppress platelet function. While effective in a large proportion of patients, a significant number of patients have further thrombotic episodes that result in death, while approximately 5% of treated patients develop clinically relevant bleeding which may require blood transfusion and can be fatal. With an ageing population, who are at a greater risk of thrombosis, the shortfall in available therapy regimes is a growing unmet clinical need in the EU. This presents a major societal problem and a need to develop new and improved anti-platelet agents that effectively target thrombosis whilst preserving haemostasis.  This is the major goal of TAPAS.